Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Oct. 02, 2026	Functional analysis of adrenocorticotropic-hormone–producing pituitary cells derived from human pluripotent stem cells in murine and primate models of hypopituitarism	R&D
Sep. 30, 2026	Topline Results from the Final Analysis of the Phase 1 Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)	R&D
Sep. 02, 2026	Sumitomo Pharma Announces Personnel Changes	Corporate
Aug. 31, 2026	Sumitomo Pharma Selected as a Constituent of Five GPIF-Adopted ESG Indexes	Sustainability
Aug. 28, 2026	Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements (Japanese GAAP)	Finances
Aug. 26, 2026	Sumitomo Pharma Selected as a Constituent of the JPX Prime 150 Index	Others

Oct. 30, 2026	2nd Quarter of FY2026 financial results announcement (scheduled to be disclosed at 3:30 p.m.), conference on 2nd quarter FY2026 financial results for Analysts, Investors, and the Press